SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-148646
Filing Date
2022-05-12
Accepted
2022-05-12 16:11:37
Documents
14
Period of Report
2022-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d315287d8k.htm   iXBRL 8-K 25253
2 EX-99.1 d315287dex991.htm EX-99.1 52332
6 GRAPHIC g315287g10h00.jpg GRAPHIC 33923
  Complete submission text file 0001193125-22-148646.txt   257581

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA sbtx-20220512.xsd EX-101.SCH 2860
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE sbtx-20220512_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sbtx-20220512_pre.xml EX-101.PRE 11710
8 EXTRACTED XBRL INSTANCE DOCUMENT d315287d8k_htm.xml XML 3474
Mailing Address 500 FAIRVIEW AVENUE NORTH, SUITE 600 SEATTLE WA 98109
Business Address 500 FAIRVIEW AVENUE NORTH, SUITE 600 SEATTLE WA 98109 206-456-2900
Silverback Therapeutics, Inc. (Filer) CIK: 0001671858 (see all company filings)

IRS No.: 811489190 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39756 | Film No.: 22917913
SIC: 2834 Pharmaceutical Preparations